Panacea Life Sciences Holdings, Inc.
PLSH
$0.0539
$0.005912.29%
| 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 50.38% | 46.59% | -10.21% | -18.54% | -8.74% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 50.38% | 46.59% | -10.21% | -18.54% | -8.74% |
| Cost of Revenue | 6.05% | 4.51% | -11.44% | -12.12% | -8.40% |
| Gross Profit | 12.45% | 10.51% | 11.93% | 9.17% | 8.25% |
| SG&A Expenses | 63.78% | 34.11% | -44.84% | -46.84% | -47.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.25% | 8.95% | -17.56% | -18.53% | -16.17% |
| Operating Income | -0.36% | 1.88% | 19.78% | 18.52% | 18.47% |
| Income Before Tax | 5.91% | 12.33% | 21.17% | 18.85% | -2.73% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 5.91% | 12.33% | 21.17% | 18.85% | -2.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5.91% | 12.33% | 21.17% | 18.85% | -2.73% |
| EBIT | -0.36% | 1.88% | 19.78% | 18.52% | 18.47% |
| EBITDA | -2.10% | 2.24% | 27.24% | 26.48% | 25.35% |
| EPS Basic | 16.72% | 17.61% | 22.70% | 8.62% | -24.87% |
| Normalized Basic EPS | 13.72% | 12.56% | 21.97% | 5.68% | -6.19% |
| EPS Diluted | 16.72% | 17.61% | 22.70% | 8.62% | -24.87% |
| Normalized Diluted EPS | 13.72% | 12.56% | 21.97% | 5.68% | -6.19% |
| Average Basic Shares Outstanding | 13.00% | 6.95% | 2.12% | -10.03% | -16.26% |
| Average Diluted Shares Outstanding | 13.00% | 6.95% | 2.12% | -10.03% | -16.26% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
